Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452318 | 1.00 | EGLN2 (0.51) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL27699633 | 0.82 | FTO (0.55) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL518833 | 0.81 | KDM4E (0.44) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL15312235 | 0.80 | KDM4E (0.63) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL31356480 | 0.80 | KDM4E (0.63) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL78249 | 0.80 | KDM4E (0.63) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL4560363 | 0.80 | MKNK1 (0.50) | KDM4EL3MBTL1ALDH1A1TSHRMAPT | |
| SCHEMBL8847897 | 0.80 | EGLN2 (0.44) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL1985357 | 0.78 | KDM4E (0.61) | EGLN2FTOKDM4ETLR7L3MBTL1 | |
| SCHEMBL2277608 | 0.78 | KDM4E (0.61) | EGLN2FTOKDM4ETLR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008414-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-01-13 | — | — | US | claimed |
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | claimed |
| US-9932335-B2 | Pyrrolopyridine or pyrazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-04-03 | — | — | US | claimed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | claimed |
| US-20160194321-A1 | PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-07 | — | — | US | claimed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | claimed |
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| EP-2173721-B1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-28 | — | — | EP | claimed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-20050155087-A1 | Method of screening compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-14 | — | — | US | claimed |
| EP-1463820-A1 | METHOD OF SCREENING COMPOUNDS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| WO-2003052106-A1 | METHOD OF SCREENING COMPOUNDS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-06-26 | — | — | WO | claimed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-4101507-A | WITH PICOLINAMIDES AND ZINC OXIDE OR MAGNESIUM OXIDE | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1978-07-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | HDAC6, HDAC1, HDAC11 | EGLN2 1706/4885FTO 4799/4885KDM4E 319/4885 |
| US-20220008414-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | EGLN2 1159/4885FTO 4864/4885KDM4E 1264/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | EGLN2 222/4885FTO 472/4885KDM4E 2350/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | EGLN2 1029/4885FTO 4750/4885KDM4E 835/4885 |
| US-20160194321-A1 | PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES | CHRM1, CHRM2, CHRM3 | EGLN2 2435/4885FTO 881/4885KDM4E 2597/4885 |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC6, HDAC1, HDAC5 | EGLN2 3516/4885FTO 4806/4885KDM4E 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.